title: Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation.
abstract: In 1402 patients allografted in Europe during the period 1990-2000 with an HLA-identical sibling in first remission (CR1), the median interval from CR1 to allotransplant (96 days) was a major prognostic factor, patients transplanted earlier having a worse outcome. We studied in depth the 414 fully evaluable patients transplanted less than 96 days after achieving CR1; in these patients, only three factors predicted for the outcome by multivariate analysis: patient age, CR1 achievement with one or more induction courses and the recipient/donor sex combination. These three factors overcame the information from cytogenetics and source of stem cells. Three prognostic groups could be identified in relation to the outcome, using a prognostic score affecting 1 to each poor risk factor (total from 0 to 3): Group 1 (good prognosis) includes patients <35 years old, achieving CR1 with one induction course and to be transplanted with any other sex combination than female to male (score 0); group 2 (intermediate) with one adverse factor (score 1); and group 3 (bad prognosis) with two or three adverse criteria (scores 2 and 3). In these three groups, the 3-year leukaemia-free survival was 56+/-5%, 48+/-4% and 29+/-4% and the overall survival was 65+/-5, 53+/-4 and 29+/-5%, respectively. Therefore, adult patients with ALL and a score of 0 or 1 are good candidates for an early transplant if they have an identical sibling donor. Patient age, response to induction and the sex of the HLA-identical family donor (if existing) are the strongest easy predictors of the outcome for an early transplant in an adult patient with ALL. No additional information is mandatory.
authors.affiliation: Centre International Greffes de Moelle, European data management office of the EBMT, Hopital Saint-Antoine, Paris, France.
authors.forename: N-C
authors.initials: NC
authors.lastname: Gorin
authors.forename: M
authors.initials: M
authors.lastname: Labopin
authors.forename: E
authors.initials: E
authors.lastname: Polge
authors.forename: C
authors.initials: C
authors.lastname: Cordonnier
authors.forename: J P
authors.initials: JP
authors.lastname: Jouet
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: B
authors.initials: B
authors.lastname: Rio
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality / Q000592:standards*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D018570:Risk Assessment; D012737:Sex Factors; D035781:Siblings; D016019:Survival Analysis; D014019:Tissue Donors; D014185:Transplantation, Isogeneic